2022
Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesEarly Detection of CancerHumansMaleMass ScreeningMiddle AgedProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesConceptsProstate cancer screeningUS Preventive Services Task ForcePSA testingCancer screeningInterrupted time series analysisCohort studyUS Preventive Services Task Force (USPSTF) recommendationDraft statementLarge national cohort studyEligible beneficiariesPSA testing ratesRetrospective cohort studyRate of PSANational cohort studyProstate-specific antigenAge-adjusted ratesTask Force recommendationsUSPSTF guidelinesMedian ageGuideline changesProstate cancerMedian numberMAIN OUTCOMEClaims dataTesting rates
2018
Medicare Cancer Screening in the Context of Clinical Guidelines
Maroongroge S, Yu J. Medicare Cancer Screening in the Context of Clinical Guidelines. American Journal Of Clinical Oncology 2018, 41: 339-347. PMID: 26886947, DOI: 10.1097/coc.0000000000000272.Peer-Reviewed Original ResearchConceptsCancer screeningScreening ratesFee-for-serviceColorectal cancer screening ratesBilling codesCancer screening ratesColorectal screening testsMedicare fee-for-serviceMedicare Part B beneficiariesMonte Carlo permutation methodMedicare FFS populationBeneficiaries per yearMedicare FFS programEvidence-based guidelinesScreening testRetrospective claims dataProstate cancer screeningPublic health issueMammography ratesFFS populationScreening trendsMedicare populationClaims dataGuideline publicationPatient preferences
2017
Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Kim S, Beard C, Martin N, Trinh Q, Nguyen P. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Annals Of Oncology 2017, 28: 1098-1104. PMID: 28453693, DOI: 10.1093/annonc/mdx041.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityProstate-specific antigenUnited States Preventive Services Task ForceRisk of prostate cancer-specific mortalityProstate cancer outcomesBlack raceMetastatic diseaseCancer outcomesProstate-specific antigen screeningRate of metastatic diseasePSA screening guidelinesCancer-specific mortalityRisk of poor outcomesStage of presentationPreventive Services Task ForceScreening-eligible ageMultivariate logistic regressionEligible populationNon-black menSEER databaseProstate cancerBlack menScreening guidelinesPoor outcomeRisk regression